In human B‐cell lymphomas, miR‐19 promotes tumour cell survival by inhibiting PTEN directly and activating AKT/mTOR pathway.22 Expression of miR‐19 is elevated in SHH medulloblastoma, a subgroup of medulloblastoma characeterized as constitutive activation of the Sonic Hedgehog pathway, anti‐miR‐19 treatment restrains proliferation of tumour cells and prolongs survival of tumour‐bearing mice23 (Figure 1). This evidence concerns the gene PTEN and medulloblastoma.